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Abstract 
The objective of this prospective randomized study was to verify whether the 
superiority of the sirolimus-eluting stent (SES) in inhibiting neointimal hyperplasia 
could be demonstrated in complex coronary lesions. The SES was compared with the 
paclitaxel-eluting stent (PES) in long lesions of the left anterior descending artery with 
intravascular ultrasound (IVUS) and quantitative angiography. Late luminal loss and 
mean neointimal hyperplasia were significantly lower in the SES group compared to the 
PES group and peri-stent plaque area was significantly reduced in the SES group only. 
Both groups had excellent IVUS and angiographic results at 9-month follow up. 
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Abbreviations 
1. SES=sirolimus-eluting stent  
2. PES=paclitaxel-eluting stent  
3. IVUS=intravascular ultrasound 
4. NIHA=mean neointimal hyperplasia area  
5. PSPA=mean peri-stent plaque area 
6. PCI=percutaneous coronary intervention 
7. MLA=minimal lumen area  
8. RVD=reference vessel diameter  
9. MLD=minimal luminal diameter 
10. LL=late luminal loss  
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Introduction 
Coronary stenting, by reducing both the acute risk of major complications and 
the incidence of restenosis, has gradually replaced conventional balloon angioplasty as 
the standard technique to accomplish percutaneous coronary interventions (PCIs) 1,2. 
However, in-stent restenosis still occurs in 10 to 50% of the patients, depending upon a 
number of clinical, angiographic, and procedural variables 3-5. 
In April 2002, the first drug-eluting stent (DES) became commercially available 
in Europe, beginning what has been called the third revolution in PCI following the 
introduction of balloon angioplasty and stents. The DES combines the advantages of a 
stainless steel scaffold with controlled release of an antiproliferative agent to prevent 
restenosis 6. Local drug delivery allows to achieve appropriate drug concentration at the 
treatment site while avoiding systemic toxic effects. 
A DES has three basic components: the stent, the coating, and the biological 
agent.  A number of DESs have been developed using different carrier stents, different 
kinds of coating, and different drugs 6,7. To ensure uniform drug delivery, the ideal DES 
should have a large surface area, minimal gaps between cells, and minimal strut 
deformation after deployment. Furthermore, these stents would need to maintain a good 
deliverability even in more complex lesions, through a low profile, good conformability 
and radial support, and appropriate flexibility. 
A variety of different formulations have been developed that provide appropriate 
stent coating for clinical use, including direct drug binding, coatings with 
phosphorylcholine, non-erodible or bioabsorbable polymers, or ceramic layers. The 
coating should not induce an excessive vascular reaction 8, should be suitable for 
sterilization, it must follow the geometric change of configuration during stent 
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expansion, be resistant to mechanical abrasion during stent implantation, and it should 
be able to release the drug in a controlled way.  A potential universal coating is unlikely, 
and different pharmacological agents may require different delivery vehicles. 
The biological agent carried by the stent should interfere with one or more steps 
involved in the restenosis process, yet preserving vascular healing. A number of 
antiproliferative, immunosuppressive, anti-inflammatory, antithrombotic, and 
prohealing drugs have been tested or are under investigation.  To date, only two DESs 
have received CE (Conformité Européenne) and FDA (Food and Drug Administration) 
approval for clinical use in Europe and in the United States, respectively: the Cypher™ 
sirolimus eluting stent (SES) (Cordis, Johnson & Johnson, Miami Lake, FL, USA), and 
the Taxus™ paclitaxel-eluting stent (PES) (Boston Scientific, Natick, MA, USA).  In 
randomized trials, both these stents have been shown to dramatically reduce late luminal 
loss, binary restenosis, and the need for repeat revascularization when compared to bare 
metal stents (BMSs) 9-13.  Sirolimus (rapamycin) is a macrocyclic lactone produced by 
Streptomyces hygroscopicus, which inhibits cellular proliferation by blocking cell cycle 
progression at the G1 to S transition 14-16, and inhibits vascular smooth muscle cell 
migration 14. In the Cypher™ stent, a combination of two non-erodible polymers 
(polyethylene-co-vinyl acetate, and poly n-butyl methacrylate [PBMA]) mixed with 
sirolimus (67%/33%) makes up the basecoat formulation which is applied to a parylene 
C-treated stent. A drug-free topcoat of PBMA polymer is applied to the stent surface to 
control the release kinetics of sirolimus (> 28 days) 6. 
Paclitaxel (taxol) is an antineoplastic agent that shifts the microtubule 
equilibrium toward assembly.  This enhances the assembly of extraordinarily stable 
microtubules, interrupting proliferation, migration, and signal transduction 17-19. In the 
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Taxus™ stent, 1 μg/mm2 paclitaxel is incorporated in a poly (lactide-co-Σ-caprolactone) 
copolymer attached to a conventional stent.  Two different release kinetics were 
evaluated: slow release (continuous drug release throughout the first 15-20 days), and 
moderate release (the drug is released within the first 2 days after stent implantation). 
To date, many randomized controlled trials on DESs have been completed. 
However, while studies on SESs represent a homogeneous group utilizing one single 
device, studies on PESs comprised a variety of devices, both non-polymer-based and 
polymer-based, which therefore need to be evaluated separately. In all these trials 
chronic total occlusion, ostial lesion, thrombus-containing lesion, unprotected left main 
PCI, acute myocardial infarction, low left ventricular ejection fraction, and multivessel 
stenting were exclusion criteria. 
 
The sirolimus-eluting stent 
Six randomized trials comparing the outcomes of patients treated with SESs and 
conventional BMSs have been concluded to date 9, 10, 12, 20-24. In these studies, SESs 
were evaluated in the treatment of de novo coronary lesions, < 33 mm long, in native 
coronary arteries 2.5 to 3.5 mm in diameter. 
The landmark Randomized Study with Sirolimus-Eluting Velocity Balloon-
Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery 
Lesions (RAVEL) trial included 238 patients with single non-complex de novo lesions. 
Remarkably, the 6-month angiographic restenosis rate of the SES group was zero, as 
well as the late loss. Intravascular ultrasound examination at follow-up further 
confirmed the marked neointimal inhibition after SES implantation 25. The clinical 
outcomes were significantly better among patients treated with the sirolimus stents, with 
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94% of patients being free of any major cardiac events at 1 year compared to 71% in the 
BMS group (p < 0.01) 9-13, 20-24. The Sirolimus-Eluting Bx VelocityTM Balloon-
Expandable Stent (SIRIUS) trial randomized 1101 patients with de novo lesions to 
sirolimus or bare stents 10. In-stent binary restenosis (within the margins of the stent) 
was reduced by 91% (3.2 vs 35.4%, p < 0.01) and in-segment restenosis (including the 
stented portion and the 5-mm segments proximal and distal to the stent) was reduced by 
75% (8.9 vs 36.3%, p < 0.01) 10. At 9 months, the incidence of major adverse cardiac 
events was significantly lower in the sirolimus group (7.1 vs 18.9%, p < 0.01), mainly 
due to a decrease in the need of target lesion revascularization (TLR) (4.1 vs 16.6%, p < 
0.01). At 12 months, the absolute difference in TLR continued to increase (4.9 vs 20%, 
p < 0.001) 26. The E-SIRIUS trial enrolled 352 patients with longer lesions and smaller 
vessels than the RAVEL and SIRIUS trials 12. Nevertheless, the 8-month in-stent 
restenosis rate was 3.9% in the sirolimus and 41.7% in the bare stent group (p < 0.01). 
Similarly, the incidence of in-segment restenosis (5-mm edges included) was 
significantly reduced (5.9 vs 42.3%, p < 0.01). The 9-month incidence of major adverse 
cardiac events was 8 vs 22.6% in the sirolimus and bare stent groups (p < 0.01). In the 
C-SIRIUS trial, which randomized 100 patients to sirolimus or conventional stenting, 
in-stent restenosis was not detected in any patient after SES implantation 20. In-segment 
restenosis occurred in 2.3% of SES patients and 52.3% of BMS patients (p < 0.001). At 
270 days, clinically-driven TLR was 4% in the SES group and 18% in the BMS group 
(p = 0.05). The Kaplan-Meier estimate of freedom from major adverse cardiac events at 
270 days was 96.0% for SES patients and 81.7% for BMS patients (p = 0.029). 
The Sirolimus-Eluting Stent in Small Arteries (SES-SMART) study was 
specifically designed to evaluate SESs in small vessels 23. The mean vessel size in the 
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patients was 2.2 mm. At 8 months, in-segment binary restenosis was 9.8% in the SES 
group and 53.1% in the control group (p < 0.001). Acute myocardial infarction and 
overall clinical events were also significantly reduced in patients who received the DES. 
All findings appeared to be independent of gender, diabetic status, and stent size 23. 
The Diabetes and Sirolimus-Eluting Stent Trial (DIABETES) assessed the 
efficacy of SESs in 160 diabetic patients with de novo coronary stenoses, half of whom 
received BMSs 24. Abciximab was recommended for all patients. There was an 88% 
reduction in late lumen loss in the SES group compared to the BMS group (from 0.44 to 
0.08 mm, p < 0.0001). Binary restenosis was reduced from 33% in the BMS group to 
7.7% in the SES group. At 9-month follow-up, there was a significant difference in TLR 
(7.5 vs 31.3%, p < 0.0001) and major adverse cardiac events (11.3 vs 36.3%, p < 
0.0001) in favor of the SES group. 
 
The Paclitaxel (polymer-coated) eluting stent 
The large variety of PESs should lead us to consider that variations in drug 
dosing, release kinetics, stent design, and stent coating technologies may result in 
different vascular reactions and efficacy. Four clinical trials utilizing polymer-coated 
PESs have been reported 11, 13, 27. Overall, more than 2300 patients with de novo lesions 
have been enrolled in the TAXUS I 27 , II 11, IV 13, and VI trials, and randomized to 
paclitaxel or bare stents. Different stent platforms with different release kinetics were 
used in these studies. The Taxus NIRx stent coated with paclitaxel (1 µg/mm2 paclitaxel 
per unit of stent surface area) in a slow-release formulation was employed in the 
TAXUS I, the same stent with both a slow-release and a moderate-release formulation 
was used for the TAXUS II. In TAXUS IV and VI, the drug was loaded onto the 
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Express stent, in the slow-release formulation in the former, and the moderate-release 
formulation in the latter. A marked reduction in neointimal proliferation and binary 
restenosis was observed in the active groups of all the trials, leading to a significant 
reduction in revascularization procedures and overall adverse cardiac events compared 
to controls 11, 13, 27. Interestingly, the TAXUS VI is the only trial specifically designed 
for long lesions (lesion length for inclusion 18-42 mm). In this trial, PESs reduced 
restenosis from 35.7 to 12.4% and repeat revascularizations from 19.4 to 9.1% (Grube 
E., personal communication). In all these studies, DESs and BMSs showed similar rates 
of subacute stent thrombosis. 
 
The Paclitaxel (direct dip-coating) eluting stent 
Paclitaxel elution from a metal stent without a polymer coating is an attractive 
choice because some polymers were associated with an exaggerated inflammatory 
response and increased neointimal hyperplasia in animal studies. However, 
contradictory clinical results have been obtained with devices utilizing direct dip-
coating of paclitaxel stents 28, 29, 30. Some of the studies evaluating paclitaxel or 
paclitaxel derivatives never came to full completion due to an unacceptable adverse 
event rate (9.4% stent thrombosis in the active arm of the Study to Compare Restenosis 
Rate between QueST and QuaDS-QP2 [SCORE] trial) 31 or did not yield sufficient 
clinical benefit to justify commercialization of the device. The European Evaluation of 
Paclitaxel Eluting Stent (ELUTES) trial 30 and the Asian Paclitaxel-Eluting Stent 
Clinical Trial (ASPECT) 29 have shown a significant dose-dependent reduction in 
restenosis with paclitaxel stents, whereas the larger RX AchieveTM Drug-Eluting 
Coronary Stent System in the Treatment of Patients with de Novo Native Coronary 
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Lesions (DELIVER-I) study failed to demonstrate the beneficial effect of these devices 
28. In the ASPECT, two different types of antiplatelet therapy were given to patients 
treated with PESs 29. This choice contributed to the relative increase in adverse events in 
the group treated with aspirin and cilostazol compared to those treated with aspirin and 
clopidogrel. 
 
The relative efficacy of the more successful DES cannot be easily assessed 
because they are most often compared with BMS. Randomized trials such as the 
Prospective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting 
and the Taxus Paclitaxel-Eluting Stent Systems (REALITY), Paclitaxel and Sirolimus 
Stents in the Real World of Interventional Cardiology (TAXI) study, Drug-Eluting Stent 
for Complex Lesions: Cordoba–Las Palmas Study (CORPAL), Sirolimus-Eluting Stent 
Compared with Paclitaxel-Eluting Stent for Coronary Revascularization (SIRTAX) 
study, Intracoronary Stenting and Angiographic Results—Drug-Eluting Stents for In-
Stent Restenosis (ISAR-DESIRE) trial, and the ISAR-Diabetes trial directly compared 
SES and PES in a wide variety of patient and lesion types.32-37 Both the SIRTAX and 
ISAR-DESIRE showed target lesion revascularisation rates that favored SES. 35,36. 
SIRTAX randomised 1012 patients to PCI of de novo coronary lesions with SES/PES 
showing at 9 months a TLR of 4,8% in SES and 8,3% in PES group (p 0,03) 35. ISAR-
DESIRE enrolled only patients with in-stent restenosis 36. However, the TAXI, 
REALITY, ISAR-DIABETES, and CORPAL studies did not show a significant 
difference between both devices 32-34, 37. TAXI trial randomised 202 patients and was 
essentially a clinical study with angiographic follow up performed only in few cases 33. 
REALITY involved 1386 patients and did not find differences in the rates of binary 
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restenosis or MACE between SES and PES 32. ISAR-DIABETES (250 patients with 
diabetes and coronary artery disease randomized to SES/PES) showed a significantly 
greater late luminal loss in PES group but not an increased rate of revascularisation for 
restenosis 37. CORPAL enrolled 515 patients with coronary lesions at high risk for 
restenosis and obtained an  angiographic and IVUS follow-up in a subgroup 
(respectively 154 and 51 pts), showing a significantly lower angiographic late loss 
(0,30±0,4 mm in SES vs 0,59±0,8 mm in PES, p<0,01) and neointimal area (0,41±0,4 
mm2 in SES vs 1,37±1,4 mm2, p<0,01) 34. Two recent meta-analyses showed that the 
use of SES was associated with lower angiographic restenosis rates and a lower 
incidence of target vessel revascularization as compared with PES 38,39 . Of note, no 
significant differences were found in the incidence of death or myocardial infarction 
between both groups. Among the PES registries, the TAXUS Stent Evaluated at 
Rotterdam Cardiology Hospital (T-SEARCH) registry is worth mention because it was 
one of the first studies to reflect real-world clinical practice. The recently published 2-
year results did not show a significant difference between PES and SES in any of the 
clinical end points.40 The much larger Strategic Transcatheter Evaluation of New 
Therapies (STENT) registry also did not show a significant difference between both 
devices at 6 months in 6659 patients. 41 
 
IVUS and DES 
Intravascular ultrasound (IVUS) is unique in its ability to assess stent 
implantation. Specifically, serial (postintervention and follow-up) IVUS can measure 
intimal hyperplasia (IH), assess acute and late acquired incomplete stent apposition, 
detect the presence and persistence of edge dissections, assess vascular responses such 
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as remodeling, study edge effects, compare overlapping with nonoverlapping segments, 
and look for causes of restenosis and thrombosis. In particular, IVUS determined 
percentage IH volume (IH volume/stent volume) has been a useful indicator of the 
ultimate clinical success or failure of a particular DES. In BMS, %IH volume averaged 
30% of stent volume; %IH volume was consistently greater in diabetics versus 
nondiabetics; and in BMS that did not restenose, IH remained stable or regressed 
slightly after 6 months.   
The sirolimus-eluting stent 
In the RAVEL (Randomized Comparison of a Sirolimus-Eluting Stent with a 
Standard Stent for Coronary Revascularization) trial, 6-month %IH volume (1 ± 3%) 
was lower with Cypher stents compared with control subjects (29 ± 20%; p < 0.001) 25. 
In the subset of diabetic patients, Cypher stent %IH volume measured 0.82 ± 1.38% (vs. 
30.2 ± 22.9% in control subjects; p = 0.008). Furthermore, Cypher stents compared 
favorably in diabetics versus nondiabetics in whom %IH volume measured 1.14 ± 
2.68% 42. 
In the SIRIUS (Sirolimus-Eluting Stent in Coronary Lesions) trial, Cypher stents 
reduced 9-month %IH volumes from 33.4% to 3.1% (p < 0.001) 10. There was a 
tendency for greater neointima suppression in the middle of the stent compared with the 
edges, the opposite of BMS 43. There was: 1) no difference in IH between lesions with 
moderate/severe calcium (arc _120°) versus no/mild calcium; 2) no difference between 
lesions with positive versus negative pre-intervention vessel remodeling; 3) no 
correlation between IH and pre-interventional plaque burden (plaque and media 
[P&M]/external elastic membrane [EEM]); 4) no effect from stent asymmetry; and 5) 
no difference between overlap versus nonoverlapped segments 44-46. Many weak 
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predictors of BMS restenosis (i.e., pre-intervention positive remodeling and pre-
intervention or residual plaque burden) were not predictive after Cypher implantation, 
because marked IH suppression masked any effect from weaker predictors. 
In the São Paulo registry, IH within Cypher stents was stable or increased 
slightly beyond the time points reported in the RAVEL (6 months) and SIRIUS (9 
months) trials.  The %IH volume in 14 patients treated with the fast-release formulation 
was 2.3% at 1 year, 9.2% at 2 years, and 9.1% at 4 years; %IH volume in 14 patients 
treated with the slow-release formulation was 2.2% at 1 year, 3.3% at 2 years, and 5.7% 
at 4 years 47-49. 
The paclitaxel-eluting stent 
In the TAXUS-II trial, 6-month %IH volume measured 7.8 ± 9.9% in slow-
release Taxus stents (vs.  23.2 ±  18.2% in control subjects) and 7.8 ±  9.7% in 
moderate-release Taxus stents (vs. 20.5 ±  16.7% in control subjects) 11. The distribution 
of IH over the length of the stent was neither increased (as in BMS) nor more 
suppressed in the center (as in Cypher) 50. 
The findings of the TAXUS-II trial were supported by the TAXUS-IV trial 51; 9-
month %IH measured 12.2 ± 12.4% in slow-release Taxus stents versus 29.4 ±  14.0% 
in control subjects (p < 0.0001). As in the TAXUS-II trial, IH was flat over the length of 
the stent. The TAXUS-V trial randomized more complex lesions than the TAXUS-IV 
trial; %IH volume measured 13.2 ± 12.0% with Taxus stents versus 31.8 ± 15.1% with 
control subjects (p < 0.0001) 52. The TAXUS-VI trial studied  moderate-release Taxus 
stents in longer lesions; %IH volume measured 10.7 ± 10.8% versus 33.0 ± 15.1% in 
control subjects (p < 0.0001) (N. J. Weissman, unpublished data,  2005). 
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A subset meta-analysis of 566 patients from the TAXUSIV, V, and VI trials 
showed: 1) %IH measured 9.8 ± 12.0% in overlapping Taxus segments versus 11.3 ± 
10.9% in nonoverlapping segments; and 2) in lesions > 26 mm in length, %IH measured 
13.4 ± 9.2% (N. J. Weissman, unpublished data, 2005) In that meta-analysis, %IH in 87 
diabetics treated with Taxus stents measured 13.7 ± 12.4%, i.e., less than the 34.6 ± 
16.7% in 75 diabetics treated with BMS (p < 0.0001) but no different from the 217 
nondiabetics treated with Taxus stents (11.6 ± 11.6%) 53.   
Two-year TAXUS-II IVUS trial data has been reported in a highly selected 
group of 32% of Taxus-treated patients who had baseline and 6 month follow-up IVUS. 
The IH continued to be significantly suppressed compared with BMS. However, IH 
increased in both the slow-release and moderate-release Taxus stents (0.64 ± 0.81 mm2 
to 0.94 ± 0.76 mm2 [p = 0.01] and 0.66 ± 0.83 mm2 to 1.06 ± 0.90 mm2 [p = 0.009], 
respectively) 54. 
 
Even if almost all studies on DES have included some IVUS analyses, few data 
are available on IVUS assessment of long, complex coronary lesions treated with the 
SES or the PES, and to date, no randomized comparison of IVUS findings has been 
reported in these subjects. Available data on lesions treated with the SES or the PES 
shows that the SES appears to exert a more powerful inhibition of neointimal growth. 
The objective of this study was to verify whether the superiority of the SES in inhibiting 
neointimal hyperplasia could be demonstrated in complex coronary lesions. 
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Methods 
Patient Selection 
Patients with stable angina, non-ST-segment elevation acute coronary syndrome, 
or documented silent ischemia undergoing coronary angiography at Pisa University 
Hospital were screened for enrollment. Inclusion criteria were: (a) presence of an 
angiographically significant stenosis in the proximal and/or mid portion of the left 
anterior descending artery; (b) American College of Cardiology/American Heart 
Association (ACC/AHA) lesion class B2 or C, requiring a stent ≥ 16 mm in length; (c) 
vessel reference diameter between 2.5 and 3.7 mm at lesion site; and (d) consent to 
undergo a follow-up angiography at nine months. Exclusion criteria were: (a) ST-
segment elevation acute myocardial infarction; (b) intolerance to aspirin or clopidogrel; 
(c) severe comorbidity; and (d) participation in another clinical study. The study 
complied with the Declaration of Helsinki and was approved by the local ethics 
committee. All patients gave written informed consent.  
 
Randomization and Treatment 
Randomization was performed after diagnostic angiography and before 
angioplasty. Sequentially numbered, sealed randomization envelopes were used, with a 
computer-generated random allocation sequence. Patients were randomized on a 1:1 
basis to treatment with a SES (Cypher, Cordis, Miami Lakes, Florida, USA) or a PES 
(Taxus, Boston Scientific, Natick, Massachusetts, USA). Stent diameter ranged from 
2.75 to 3.50 mm; minimum stent length was 18 mm for the SES and 16 mm for the PES. 
Shorter stents could be used as a second stent for complete lesion coverage, or to treat 
edge dissection. In case of inability to deliver a single stent to cover the whole length of 
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the lesion, the use of two shorter stents with overlapping edges was allowed. If a 
mixture of drug-eluting stents could not be avoided, the patient was excluded from the 
study. 
Before percutaneous coronary intervention (PCI), all patients received ≥ 100 mg 
of aspirin and a 300 mg loading dose of clopidogrel was administered before or at the 
time of PCI. PCI was performed by radial approach  in more than 90% of patients. In 
our center this is first choice vascular access because of less bleeding complications and 
best patient’s comfort than femoral approach, with similar procedural success. After 
crossing the stenosis with a guidewire, if needed, the lesion was pre-dilated with a 
balloon catheter; then, according to randomization,  SES or PES was implanted. At the 
beginning of the procedure  unfractionated heparin (70 U/kg of body weight) was 
administered and ACT (activated clotting time) was periodically checked to be between 
250-300 sec.  Use of glycoprotein IIb/IIIa inhibitors was at the physician’s discretion. 
Successful intervention was defined as a patent vessel with antegrade Thrombolysis In 
Myocardial Infarction (TIMI) flow grade 3 and angiographic residual stenosis<50%. 
Patients were discharged on aspirin 100 mg daily indefinitely, and clopidogrel 75 mg 
daily for ≥ 6 months after PCI. In addition, all patients were discharged on simvastatin 
indefinitely, at a daily dose of 20 mg or 40 mg, as necessary to obtain LDL-cholesterol 
levels of<110 mg/dL. 
 
IVUS Analysis 
A commercially available IVUS system (Boston Scientific, Natick, Massachusetts, 
USA) was used. All IVUS studies were performed at the end of the procedure, after the 
intracoronary administration of nitroglycerin 200 μg. The IVUS catheter was advanced 
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over the same guidewire used for PCI at least 10 mm distal to the stent, and imaging 
was performed to at least 10 mm proximal to the stent, with a motorized transducer 
pullback speed of 0.5 mm/s. IVUS images were recorded onto S-VHS tape and 
analyzed by two expert readers blinded to the treatment arm, with intra-observer and 
inter-observer agreements of r=0.96 and r=0.91, respectively. The inter-observer 
variability was assessed comparing the measurement of lumen volume in 15 recordings. 
Intra-observer variability was assessed by reanalyzing 15 recordings 1 month after the 
initial analysis. IVUS characteristics were identified according to the criteria of the 
ACC Clinical Expert Consensus document on IVUS 55, using computerized planimetry 
(Tapemeasure, Indec Inc., Mountain View, California). 
The external elastic membrane, stent, and lumen contours were identified, both at 
baseline and follow-up, every millimeter within the stented segment by semiautomatic 
detection contour mode. When the external elastic membrane could not be identified 
(due to acoustic shadowing) over a>90° arc, it was not measured. If the external elastic 
membrane could not be measured in>75% of the stent length, the patient was excluded 
from the study. The total vessel volume, stent volume, and lumen volume were 
measured, and the mean vessel area, mean stent area, and mean lumen area, were 
calculated as the ratio of the corresponding volume to the analyzed length. The minimal 
lumen area (MLA) was also measured. The length of each stent that was free of 
IVUS-detectable neointimal hyperplasia was determined. The following parameters 
were calculated: mean peri-stent plaque area (PSPA, defined as [(vessel area)-(stent 
area)], PSPA% [defined as PSPA/(vessel area) x 100], mean neointimal hyperplasia 
area [NIHA, defined as (stent area)-(lumen area) at follow-up], and NIHA% [defined as 
 19
NIHA/(stent area) x 100]. Minimal in-stent lumen area after implantation was 
considered optimal when>6 mm2 56. 
Incomplete stent apposition was defined as a separation of at least one stent strut 
from the intimal surface of the arterial wall. Incomplete apposition at nine months was 
considered “persistent” if already present post-procedure, and “late-acquired” if it was 
not present after implantation 57. 
 
Quantitative Coronary Angiography 
Coronary angiograms at baseline, immediately after PCI, and at follow-up were 
performed in at least two orthogonal views after intracoronary administration of 
nitroglycerin 0.2 mg. Care was taken to avoid vessel overlapping and to obtain the same 
views at baseline and follow-up. Angiograms were analyzed by two experienced readers, 
unaware of treatment allocation, with the use of an automated edge-detection system 
(Quantcor Siemens System, Siemens AG, Erlangen, Germany). The intra-observer and 
inter-observer agreements were r=0.95 and r=0.88, respectively. The inter-observer 
variability was assessed comparing the measurement of minimal lumen diameter in 15 
angiograms. Intra-observer variability was assessed by reanalyzing 15 angiograms 1 
month after the initial analysis. Parameters measured were: the reference vessel 
diameter (RVD), the minimal luminal diameter (MLD), the percent stenosis [defined as 
(RVD-MLD)/RVD x 100], and the late luminal loss [LL, defined as (MLD after PCI)-
(MLD at follow-up)]. All angiographic measurements of the target lesion were obtained 
within the stent and within its proximal and distal 5 mm margins. 
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Study End Points 
The primary pre-specified end point was the comparison of NIHA% at follow-up 
between SES and PES use. Secondary end points included the comparison of: (1) 
change in PSPA% from baseline to follow-up; and (2) angiographic LL at follow-up. 
Major adverse cardiac events were assessed at nine months, but were not an end point. 
They included death from cardiac causes, myocardial infarction, and target-lesion 
revascularization. Myocardial infarction was defined as an increase in creatine kinase to 
more than twice the upper limit of the normal range, with elevation of troponin I. 
Target-lesion revascularization was defined as revascularization for a stenosis within the 
stent or its 5 mm borders.  
 
Statistical Analysis 
At the time of study design, IVUS data on the SES and the PES in the literature 
involved short coronary lesions in small populations, with a NIHA% of 6.6±5.5% for 
the SES 48, and of 7.8±9.9% (0.7±0.9 mm2) for the PES 11. Since total stented length 
increases the risk of in-stent restenosis also for drug eluting stents 58, we anticipated a 
60% increase in NIHA% in long, complex lesions. Thus a NIHA% of 9±5% and of 
13±7% with the SES and the PES, respectively, was anticipated. Consequently, a total 
of 74 patients provided 81% power to detect a 4% absolute difference in NIHA%, with 
a significance level of 0.05. Allowing for 25% attrition due to lack of follow-up 
angiography and insufficient IVUS quality, we calculated that 100 patients would need 
to be enrolled. 
Data are presented as frequencies or mean ± SD. Comparisons between the SES 
and the PES were performed with the 2-tailed, unpaired t-test or the Mann-Whitney test 
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for continuous parameters, the paired t-test for change from post-procedure to follow-up, 
and the Fisher exact test for categorical variables. Correlations between NIHA and 
PSPA% post-procedure and between angiographic LL and NIHA% were performed by 
linear regression analysis. Significance was set at alpha of 0.05. 
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Results 
Between May 2004 and April 2005, 101 patients were enrolled in the study. 
Figure 1 depicts the flow of participants throughout the study. Complete IVUS analysis 
was obtained in 42 patients receiving the SES and 43 receiving the PES.  
No significant differences in baseline clinical and angiographic characteristics between 
the two groups were found (Tables I and II). The degree of coronary atherosclerosis was 
indicated by the high prevalence of multivessel disease (75.3%), previous myocardial 
infarction (30.6%), and diabetes mellitus (24.7%), and by lesion length (mean 20.6±9.4  
mm, range 12-49 mm). A trend towards a larger reference vessel diameter in the PES 
group was found (p=0.09). 
Procedural characteristics, including the number of stents per lesion, stent 
diameter and length, and the rate of direct stenting, were also similar between the two 
groups (Table II). Delivery of the single long stent initially chosen failed in two SES 
and one PES patients (p>0.2). 
 
IVUS Results 
Mean vessel, stent, and lumen areas were similar in the SES and PES groups, both 
after stent implantation and at 9-month follow-up (Table III). The changes in mean 
vessel, plaque, and lumen areas at follow-up are represented in Figure 2. Mean lumen 
area showed a significant reduction in both groups (p=0.004 and p<0.001, for the SES 
and PES groups, respectively), related to the development of neointimal hyperplasia. 
The reduction in lumen area at follow-up was significantly higher in the PES group 
(p=0.002). Conversely, NIHA and NIHA%, the primary end point of the study, were 
significantly smaller in the SES group (p<0.001).  
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The stent length free of IVUS-detectable neointimal hyperplasia was significantly 
shorter in the PES group (p<0.001). More than 75% of stent length was neointimal 
hyperplasia-free in 59.5% of SES vs. 25.6% of PES (p=0.002), while less than 25% of 
stent length was neointimal hyperplasia-free in 9.5% of SES vs. 41.9% of PES 
(p=0.001). Neointimal hyperplasia-free stent length was inversely correlated with 
NIHA% in both SES and PES (p<0.001) (Fig. 3). 
Mean vessel area and PSPA in the SES group showed a trend towards a reduction 
at follow-up (p=0.14 and p=0.09, respectively), while in the PES group they showed no 
significant change (Table III) (Fig. 2). In terms of PSPA%, the reduction in the SES 
group from post-procedure to follow-up reached statistical significance (p=0.008), 
making the mean change in PSPA% from post-procedure to follow-up significantly 
different between the SES and PES groups (-2.1±4.8 vs 0.1±3.4%, respectively; p=0.01). 
No correlation was found between NIHA at follow-up and PSPA% post-procedure 
(r=0.062, p>0.2). 
An in-stent MLA of>6 mm2 after implantation (72.6 vs 74.4%, in SES and PES 
groups, respectively; p>0.2) was associated with no target-lesion revascularization 
during follow-up (0 vs 9.2%; p=0.06), and with minimal binary in-stent restenosis (1.6 
vs 13.6%; p=0.05), compared with an in-stent MLA ≤6 mm2. 
Incomplete stent apposition was comparable in the SES and PES groups, both 
after implantation (7.1 vs 9.3%, respectively; p>0.2) and at nine months (14.3 vs 11.7%; 
p>0.2), being persistent in 4.8 vs 4.7% of patients in the SES and PES groups, 
respectively (p>0.2), and late-acquired in 9.5 vs 7.0% (p>0.2). Incomplete apposition 
was never associated with a major adverse cardiac event. 
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Subgroup analysis for patients with and without acute coronary syndrome (ACS) 
confirmed general results with a significant lower NIHA%  for SES treated patients in 
both subgroups (ACS: NIHA% 7,9 ± 4,5 in SES vs 13,9 ± 8,8 in PES, p = 0,003. No 
ACS: NIHA% 6,7 ± 3,9 in SES vs 17,8 ± 6,7 in PES, p < 0,0001). 
A typical example of IVUS findings for both the SES and the PES is depicted in 
Figure 4. 
 
Angiographic Results 
The mean in-stent LL at follow-up was 0.16±0.19 mm in the SES group and 
0.32±0.33 mm in the PES group (p=0.003) (Table IV). The mean percent stenosis was 
quite low in both groups (10.7% vs 16.8% for the SES and PES groups, respectively; 
p=0.04), with a rate of in-stent binary restenosis of only 2.4% vs 7.0% (p>0.2). With 5 
mm proximal and distal stent margins, the rate of in-segment restenosis was 2.4% vs 
9.3%, for the SES and PES groups, respectively (p>0.2). A highly significant linear 
correlation between angiographic LL and NIHA% was observed in the entire population 
(r=0.567, p<0.001). 
 
Major Adverse Cardiac Events 
The overall rate of major adverse cardiac events was very low and not statistically 
different in both groups (4.8 vs 6.8%, for the SES vs the PES, respectively; p>0.2), with 
one cardiac death in the PES group (0 vs 2.3%, for the SES vs the PES, respectively; 
p>0.2), and one myocardial infarction and one target-lesion revascularization in each 
group (2.4 vs 2.3%; p>0.2). 
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Discussion 
Not surprisingly, in light of previous angiographic and clinical studies in short 
lesions, the present study demonstrates that the SES reduces neointimal tissue 
proliferation significantly more than the PES in long, complex coronary lesions. 
However, the NIHA% was remarkably low for both types of drug-eluting stents, 
compared with previous data on bare-metal stents (30-40%) 51,60, and in agreement with 
previously reported IVUS data on the SES 10, 47-49, 25 and the PES. 11, 50, 51, 54, 61  
In particular, in our SES population, with a mean lesion length 21.2 mm, the 
NIHA% was 7.4%, which is higher than that reported with SESs for shorter lesions at 8-
12 months follow-up: 2.3% was reported in the first series from São Paulo, Brazil 
(mean lesion length 12.9 mm) 47, 1% in the RAVEL trial (mean lesion length of 14.4 
mm) 25, 1.2% in the E-SIRIUS trial (mean lesion length of 15.5 mm) 62, and 3.1% in the 
SIRIUS trial (mean lesion length of 14.4 mm) 10. Interestingly, in the first series by São 
Paulo, NIHA% appeared to increase to 6.6% at two years follow-up 48, and to 7.9% at 
four years 49.  
Regarding the PES, in our population with mean lesion length 20.1 mm, the 
NIHA% (15.4%) was higher than the 7.8% reported in the TAXUS II trial with a mean 
lesion length 10.6 mm 11, but similar to the 12.2% of the TAXUS IV trial (mean lesion 
length 12.5 mm) 51, and the 13.1% of the TAXUS V trial (mean lesion length 17.3 mm) 
61.  
The present study describes, for the first time in the literature, a direct comparison 
of IVUS results after SES and PES implantation for long lesions. Most published IVUS 
reports involve short lesions treated with a single SES 47-49, 25 or PES 11, 50, 51 . Fewer 
IVUS data involve more complex lesions, with use of multiple SESs 10,62 or PESs 61. 
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The only randomized comparison of the SES and the PES in complex lesions, the 
CORPAL trial, has only been presented orally 34. 
The length of stent free of IVUS-evident neointimal hyperplasia has been reported 
to be greater in a non-polymeric paclitaxel-eluting stent than in the corresponding bare-
metal stent, and to correlate inversely with NIHA% 63. In the present study, the inverse 
correlation with NIHA% was confirmed both for Cypher and Taxus stents (p<0.001). 
Interestingly, the mean neointimal hyperplasia-free stent length in SES was almost 
double than in PES (p<0.001), and IVUS-detectable neointimal hyperplasia was 
observed in over 75% of stent length in 41.9% of PES vs only 9.5% of SES (p=0.001). 
Thus, neointimal hyperplasia inside PES is often represented along the entire stent 
length, while SES appear neointimal hyperplasia-free for most of their length. However, 
since the assessment of stent endothelization is below the resolution of IVUS 63, the 
absence of IVUS-detectable hyperplasia does not imply the absence of re-
endothelization. 
There was no correlation between neointimal hyperplasia and post-procedural 
peri-stent plaque burden in our study. This finding is in agreement with previous reports 
showing that suppression of neointimal proliferation occurs irrespective of residual 
plaque burden after procedures with both the SES 45 and the PES 50. Late-acquired 
incomplete stent apposition was infrequent in both the SES and PES groups (9.5 vs 
7.0%, p>0.2) in the current study, which is consistent with a recent large, retrospective 
study by Hong et al. 64, indicating a prevalence of 13.2% with the SES and 8.4% with 
the PES in a real-world population. The number of patients with late-acquired 
incomplete stent apposition in our study was too small to draw any conclusions about its 
possible mechanism or clinical relevance. 
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Although the absolute changes in vessel and plaque area from baseline to follow-
up in the current study were small and did not reach statistical significance, the 
reduction in PSPA% in the SES group was significant. This finding is in contrast to 
previous reports showing no such variations at 6-month follow-up 25. With regard to 
PES, we did not observe significant changes in PSPA%, which is in agreement with the 
TAXUS IV trial 51 
In our opinion, factors other than the stent-eluted drug may play a major role in 
peri-stent plaque changes. We recently demonstrated that treatment with simvastatin 20 
mg/day in normocholesterolemic patients undergoing bare-metal stent implantation 
significantly reduces PSPA% compared with placebo (-14% vs +6%) 60. This 
observation, together with the apparent clinical benefits of statin treatment, underlies the 
aggressive lipid-lowering approach (aiming for an LDL-cholesterol level<110 mg/dL) 
we routinely use with all patients undergoing coronary interventions. At follow-up, 93% 
of SES patients and 95% of PES patients were on statins. Statin treatment may play a 
role in the observed reduction in PSPA% in the SES group in our study, and may mask 
the positive remodeling tendency described with the PES in the TAXUS II trial 1 
We observed a trend for a reduction of vessel area in SES group and not in PES 
group; the effects of DES on the vessel wall have not been fully investigated with few, 
discordant findings in literature. In an analysis of 30 patients in the Sao Paulo registry, 
vessel area did not change in the first 2 year after Cypher stent implantation but 
decreased between 2 and 4 year 65.  In an analysis of the TAXUS II trial patients, there 
was a greater 6-month increase in vessel area in the moderate-release group compared 
with control subjects but not in the slow- release group, suggesting a dose dependent 
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drug effect 50; at 2 year  the 6-month vessel area increase regressed completely in the 
slow-release group but only incompletely in the moderate-release group 54. 
An MLA >6 mm2 has been reported to reduce the risk of target-lesion 
revascularization and qualifies an “optimal IVUS result” 56. In our SES and PES 
populations, an MLA >6 mm2 post-procedure was associated with a very low rate of 
angiographic binary in-stent restenosis (1.6% vs 13.6%; p=0.05), and a with no need for 
target-lesion revascularization during follow-up. 
In agreement with the IVUS findings, quantitative angiography in our study 
showed a significantly lower LL with the SES than the PES (0.16±0.19 vs 0.32±0.33 
mm). In fact, a tight linear correlation between NIHA% and LL was observed 
(P<0.001). In-stent LL values are comparable to those reported in other randomized 
trials comparing the SES and the PES, such as the SIRTAX trial (0.12±0.36 vs 
0.25±0.49 mm with the SES and the PES, respectively; p<0.001) 35, the ISAR-
DIABETES trial (0.19±0.44 vs 0.46±0.64 mm; p<0.001) 37, and the REALITY trial 
(0.09±0.43 vs 0.31±0.44 mm; p<0.001) 32. Angiographic restenosis rates in the present 
study were also similar to those reported in the literature, but the population size was 
too small to allow meaningful considerations. 
The present study was not powered to detect differences in clinical end points; 
however, the rate of major adverse cardiac events was low and comparable between the 
two groups. Our data confirm the results of subgroup analyses of patients with a 
stenosis in the left anterior descending artery in the SIRIUS 66 and TAXUS IV 67 trials, 
showing a 1-year binary in-stent restenosis rate of 2.0% and 8.7%, respectively, and a 
target-lesion revascularization rate of 6.0% and 5.8%, respectively. In a recent meta-
analysis of six randomized trials comparing the clinical and angiographic outcome of 
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SES and PES implantation, Kastrati et al. concluded that patients receiving the SES 
have a significantly lower risk of restenosis and target-vessel revascularization 38. 
However, until results of a multicenter study with an adequately powered clinical end 
point are available, the SES and the PES should be considered clinically equivalent.  
It is important to keep in mind that Cypher stent and Taxus stent differ not only 
for eluted drug but even for polymer and stent geometry. Different performance of two 
devices could so depend at least in part on difference of polymer and stent design. 
However it’s almost impossible to analyze separately the effects of three components; 
that’s why we think it’s more correct to ascribe results to the whole device rather than to 
the eluted-drug. 
This study is limited by the absence of an IVUS core lab. However, we perform 
an average of 150 IVUS examinations per year, thus providing reliable expertise in the 
evaluation of IVUS images. Secondly, the identification of the external elastic 
membrane beyond the stent struts can be difficult or even impossible due to acoustic 
shadowing and presence of side branches, making the measurement of vessel volumes 
unreliable. In order to improve the quality of our data, we excluded those patients in 
whom the external elastic membrane could not be identified in>75% of stent length, and 
calculated the mean vessel area as the ratio of vessel volume to the actually analyzed 
length. We also acknowledge that the inclusion of patients with acute coronary 
syndromes and the discretional administration of glycoprotein IIb/IIIa inhibitors may 
have had confounding effects on neointimal proliferation. Finally, the sample size was 
too small to compare the clinical outcome, which was not an end point of the study, but 
it was adequate for the prespecified comparison of neointimal hyperplasia.  
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Whether or not the use of the SES (with the lower neointimal hyperplasia 
formation) provide superior clinical outcomes in the prognostically important left 
anterior descending artery cannot be answered in this study but is certainly an area 
deserving further investigation in future studies. 
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Conclusions 
The present study demonstrates that both the SES and the PES cause limited 
neointimal hyperplasia in complex lesions, with a significant difference in favor of the 
SES. Comparison with IVUS data obtained in previous studies involving shorter lesions 
shows a higher neointimal net volume obstruction for both the SES and PES in more 
complex lesions and this was particularly evident for the PES. The difference in 
neointimal hyperplasia observed between the SES and the PES in the present study, 
however, does not translate into higher rates of angiographic in-stent and in-segment 
restenosis. 
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Appendix 
Table I. Baseline Clinical Characteristics 
 
Characteristic 
SES 
42 patients 
PES 
43 patients p 
Age (yr) 61±11 64±10 0.12 
Male sex, n (%) 36 (85.7) 34 (79.1) > 0.2 
Current smoker, n (%) 20 (47.6) 18 (41.9) > 0.2 
Diabetes mellitus, n (%) 13 (31.0) 8 (18.6) 0.19 
Hypertension, n (%) 28 (66.7) 26 (60.5) > 0.2 
Hyperlipidemia, n (%) 30 (71.4) 26 (60.5) > 0.2 
Dialysis, n (%) 3 (7.1) 0 (0) 0.12 
Previous myocardial infarction, n (%) 15 (35.7) 11 (25.6) > 0.2 
Acute coronary syndrome, n (%) 19 (45.2) 22 (51.2) > 0.2 
Multivessel disease, n (%) 31 (73.8) 33 (76.7) > 0.2 
Left ventricular ejection fraction (%) 50±8 51±8 > 0.2 
 
SES=sirolimus-eluting stent 
PES=paclitaxel-elutingstent
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Table II. Baseline Angiographic Characteristics and Procedural Results 
Characteristic 
SES 
42 lesions 
PES 
43 lesions p 
ACC/AHA lesion class, n (%)    
B2 24 (57.1) 28 (65.1) > 0.2 
C 18 (42.9) 15 (34.9) > 0.2 
Bifurcated lesion, n (%) 5 (11.9) 4 (9.3) > 0.2 
Ostial lesion, n (%) 2 (4.8) 2 (4.7) > 0.2 
Severe calcification, n (%) 1 (2.4) 0 (0) > 0.2 
Before procedure    
Lesion length (mm) 21.2±11.2 20.1±7.2 > 0.2 
Diameter of reference vessel (mm) 2.80±0.23 2.91±0.37 0.09 
Minimal luminal diameter (mm) 0.95±0.27 0.86±0.42 > 0.2 
Stenosis (%) 66.2±8.6 70.8±13.6 0.17 
Chronic total occlusion, n (%) 1 (2.4) 3 (7.0) > 0.2 
During procedure    
Maximal stent diameter (mm) 3.0±0.2 3.1±0.3 > 0.2 
Mean number of stents, n 1.19±0.40 1.09±0.29 0.20 
Total stent length (mm) 26.6±10.6 24.8±8.0 > 0.2 
Direct stenting, n (%) 17 (40.5) 19 (44.2) > 0.2 
Unsuccessful initial implantation, n (%)* 2 (4.8) 1 (2.3) > 0.2 
Final treatment success, n (%) 42 (100) 43 (100) > 0.2 
Immediately after procedure    
Final in-stent minimal luminal diameter (mm) 2.64±0.38 2.72±0.47 > 0.2 
Final in-stent stenosis (%) 5.5±11.9 6.7±10.5 > 0.2 
 
* defined as unsuccessful implantation of the first single stent chosen to cover the whole 
lesion. 
ACC/AHA=American College of Cardiology/American Heart Association
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Table III. Intravascular Ultrasound Measurements 
In-Stent 
SES 
42 lesions 
PES 
43 lesions p 
Vessel area (mm2)    
Post-procedure 16.08±5.55 15.69±3.61 > 0.2 
9-month follow-up 15.30±4.04 15.73±3.70 > 0.2 
P 0.14 > 0.20  
Stent area (mm2)    
Post-procedure 8.13±2.46 8.23±1.86 > 0.2 
9-month follow-up 8.07±1.80 8.21±1.78 > 0.2 
P > 0.20 > 0.20  
Lumen area (mm2)    
Post-procedure 8.13±2.46 8.23±1.86 > 0.2 
9-month follow-up 7.46±1.60 7.01±1.94 > 0.2 
P 0.004 < 0.001  
Peri-stent plaque area (mm2)    
Post-procedure 7.95±3.62 7.46±2.30 > 0.2 
9-month follow-up 7.23±2.79 7.52±2.49 > 0.2 
P 0.09 > 0.20  
Peri-stent plaque area percent (%)    
Post-procedure 48.1±8.0 46.9±6.9 > 0.2 
9-month follow-up 46.0±7.9 47.0±7.1 > 0.2 
P 0.008 > 0.20  
Neointimal hyperplasia area (mm2)    
9-month follow-up 0.61±0.41 1.20±0.56 < 0.001 
Neointimal hyperplasia area percent, %    
9-month follow-up 7.4±4.2 15.4±8.1 < 0.001 
Neointimal hyperplasia-free stent length, %    
9-month follow-up 69.8±29.4 43.9±34.8 <0.001 
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Table IV. Angiographic Results at Follow-up 
 
Variable 
SES 
42 lesions 
PES 
43 lesions p 
Diameter of reference vessel, mm 2.79±0.29 2.85±0.38 > 0.2 
Minimal luminal diameter, mm 2.48±0.44 2.39±0.58 > 0.2 
Stenosis, % 10.7±14.2 16.8±13.2 0.04 
Late luminal loss, mm 0.16±0.19 0.32±0.33 0.003 
In-stent binary restenosis, % 2.4 7.0 > 0.2 
In-segment binary restenosis, % 2.4 9.3 > 0.2 
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Figure 1. 
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Figure 2.  
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure Legends 
  
Figure 1. Flow of participants through the study. IVUS=intravascular ultrasound. 
 
Figure 2. Averaged changes (follow-up minus post-procedure) in vessel, plaque, and 
lumen areas in the stented segment. 
 
Figure 3. Correlation of percent neointimal hyperplasia-free stent length and percent 
neointimal hyperplasia area in paclitaxel (solid circles – solid regression line) and 
sirolimus-eluting stents (open diamonds – dashed regression line). 
 
Figure 4. Example of IVUS semiautomatic detection of vessel area (red line), stent area 
(green line) and lumen area (yellow line). 
 
Figure 5. IVUS evaluation of SES (A) and PES (C) immediately post stent deployment 
and at follow-up (respectively B and D). PES shows greater intra-stent neointimal 
hyperplasia (seven o’clock). 
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